TherapeuticsMD | 10-Q: Quarterly report
Express News | TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
Express News | TherapeuticsMD Inc - Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Express News | TherapeuticsMD Q1 Operating Expenses USD 1.5 Million
Express News | TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
Press Release: TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD Announces Full Year 2023 Financial Results -- Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)--March 29, 2024-- TherapeuticsMD, Inc. ("TherapeuticsMD
25 Countries With Highest Abortion Rates
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indic
TherapeuticsMD(TXMD.US) Officer Sells US$43,683.9 in Common Stocks
$TherapeuticsMD(TXMD.US)$ Officer Walker Marlan D sold 19,050 shares of Common Stocks on Dec 6, 7, 2023 at an average price of $2.2931 for a total value of $43,683.9.Source: Announcement What is state
Stocks to Watch: Getty Images, TherapeuticsMD, Solid Biosciences
By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8% in after-market trading. TherapeuticsMD,
TherapeuticsMD Exploring Strategic Alternatives for Company
TherapeuticsMD Q3 EPS $(0.13) Misses $(0.05) Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 95.27 percent increase over losses of $(2.7
Therapeutics MD GAAP EPS of -$0.13
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Necessary >TXMD
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Neces
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company